Actinium Pharmaceuticals, Inc. (ATNM) Stock Price & Analysis

Actinium Pharmaceuticals, Inc. (ATNM) fell 4.72% to USD 1.01 as of June 10, 2026 at 07:32 UTC, according to Nexqual real-time market data.

ATNM last closed at USD 1.06; the session ranged USD 1.01–1.1 on volume of 132,618 shares. Market capitalization is $31.69M, with a 52-week range of USD 0.95–1.89 (ASE). Source: Nexqual, June 10, 2026 at 07:32 UTC.

Key Statistics (as of June 10, 2026 at 07:32 UTC)

Technical Analysis (ATNM)

Nexqual's technical model rates ATNM "SELL" based on 1 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 07:32 UTC.

Analyst Ratings (ATNM)

Wall Street analysts rate ATNM "Buy" based on 5 analysts, with a mean price target of USD 5 (range USD 2–9), per Nexqual as of June 10, 2026 at 07:32 UTC.

Earnings (ATNM)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 07:32 UTC.

Financials & Fundamentals (ATNM)

Source: Nexqual, June 10, 2026 at 07:32 UTC.

Financial Health Score (ATNM)

Nexqual rates Actinium Pharmaceuticals, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 07:32 UTC.

Ownership (ATNM)

Source: Nexqual, June 10, 2026 at 07:32 UTC.

Leadership (ATNM)

Actinium Pharmaceuticals, Inc. is led by Sandesh C. Seth M.B.A., M.S. (age 61), CEO, Principal Financial Officer & Chairman, per Nexqual as of June 10, 2026 at 07:32 UTC.

Major Backers & Investors (ATNM)

Notable institutional backers of Actinium Pharmaceuticals, Inc. include Acadian Asset Management. LLC, Millennium Management, Renaissance Technologies, according to Nexqual as of June 10, 2026 at 07:32 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 07:32 UTC.

From Actinium Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-03-30)

Key Strengths & Strategy (as disclosed to the SEC)

• This vertical integration provides us with significant strategic flexibility and insulates us from supply chain disruptions that have historically challenged radiopharmaceutical development.   Strong Intellectual Property Position   We have built an intellectual property portfolio comprising approximately 250 issued patents and pending patent applications, including critical composition of matter patents, method of use patents, and proprietary Ac-225 production technology.
• We also rely on trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position.   Our intellectual property portfolio comprises approximately 250 patents and patent applications across multiple jurisdictions.
• In addition, we will opportunistically seek partnerships to manufacture Ac-225 utilizing our patented cyclotron production technology.   6     Continue Platform Innovation and Pipeline Expansion   We are committed to continued innovation in radiopharmaceutical discovery and development.
• We must also comply with regulations governing the transportation of radioactive materials, including such regulation by the US Department of Transportation.   The FDA has issued guidance documents specific to radiopharmaceuticals that address topics including dosimetry assessments, clinical trial design, and manufacturing controls.

Partnerships

• This positions Actimab-A to potentially expand the $40+ billion PD-1 inhibitor market.   De-Risked Late-Stage Hematology Franchise with Near-Term Partnership Potential   Our hematology programs are supported by extensive clinical validation and represent potential near-term value creation opportunities.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 07:32 UTC. This page is informational and not investment advice.